

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 4/1/08
Version 2008.2

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ACNE AGENTS, TOPICAL	ANTIBIOTICS		A trial of 30 days of one of the preferred agents in each category will be required before a non-preferred agent will be authorized. (In cases of pregnancy, a trial of retinoids will not be required.) PA required after 17 years of age for tretinoin products.
	AKNE-MYCIN (erythromycin) clindamycin erythromycin	CLEOCIN-T (clindamycin) CLINDAGEL (clindamycin) CLINDAREACH (clindamycin) EVOCLIN (clindamycin)	
	RETINOIDS		
	RETIN A (tretinoin) ^{CL} RETIN-A MICRO (tretinoin) ^{CL} TAZORAC (tazarotene) tretinoin ^{CL}	DIFFERIN (adapalene)	
OTHERS			
AZELEX (azelaic acid) BENZAC WASH (benzoyl peroxide) BENZASHAVE (benzoyl peroxide) benzoyl peroxide benzoyl peroxide/urea DUAC (benzoyl peroxide/ clindamycin) erythromycin/benzoyl peroxide sodium sulfacetamide	BENZACLIN GEL (benzoyl peroxide/clindamycin) BENZAGEL (benzoyl peroxide) BENZAMYCIN PAK (benzoyl peroxide/erythromycin) BENZIQU (benzoyl peroxide) BREVOXYL (benzoyl peroxide) CLINAC BPO (benzoyl peroxide) DESQUAM-X (benzoyl peroxide) INOVA (benzoyl peroxide) INOVA 4/1 (benzoyl peroxide/salicylic acid) KLARON (sodium sulfacetamide) LAVOCLEN (benzoyl peroxide) NEOBENZ MICRO (benzoyl peroxide) NUOX (benzoyl peroxide/sulfur) PLEXION (sulfacetamide sodium/sulfur) sulfacetamide sodium/sulfur in urea vehicle sulfacetamide sodium/sulfur w/sunscreens SULFOXYL (benzoyl peroxide/sulfur) TRIAZ (benzoyl peroxide) ZACLIR (benzoyl peroxide) ZIANA (clindamycin/tretinoin) ZODERM (benzoyl peroxide)		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 4/1/08
Version 2008.2

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ALZHEIMER'S AGENTS	CHOLINESTERASE INHIBITORS		A trial of a preferred agent will be required before a non-preferred agent in this class will be authorized.
	ARICEPT (donepezil) ARICEPT ODT (donepezil) EXELON (rivastigmine)	COGNEX (tacrine) RAZADYNE (galantamine) RAZADYNE ER (galantamine)	
	NMDA RECEPTOR ANTAGONIST		
	NAMENDA (memantine)		
ANALGESICS, NARCOTIC - SHORT ACTING (Non-parenteral)	APAP/codeine ASA/codeine codeine dihydrocodeine/ APAP/caffeine hydrocodone/APAP hydrocodone/ibuprofen hydromorphone levorphanol morphine oxycodone oxycodone/APAP oxycodone/ASA pentazocine/APAP pentazocine/naloxone propoxyphene/APAP ROXICET (oxycodone/acetaminophen) tramadol tramadol/APAP VOPAC (codeine/acetaminophen)	ACTIQ (fentanyl) butalbital/APAP/caffeine/codeine butalbital/ASA/caffeine/codeine butorphanol COMBUNOX (oxycodone/ibuprofen) DARVOCET (propoxyphene/APAP) DARVON (propoxyphene) DEMEROL (meperidine) DILAUDID (hydromorphone) fentanyl FENTORA (fentanyl) FIORICET W/ CODEINE (butalbital/APAP/caffeine/codeine) FIORINAL W/ CODEINE (butalbital/ASA/caffeine/codeine) LORCET, LORTAB (hydrocodone/APAP) LYNOX (oxycodone/APAP) meperidine OPANA (oxymorphone) OXYFAST, OXYIR (oxycodone) PANLOR (dihydrocodeine/ APAP/caffeine) PERCOCET (oxycodone/APAP) PERCODAN (oxycodone/ASA) propoxyphene ROXANOL (morphine) TALACEN (pentazocine/APAP) TALWIN NX (pentazocine/naloxone) TYLENOL W/CODEINE (APAP/codeine) ULTRACET (tramadol/APAP) ULTRAM (tramadol) VICODIN (hydrocodone/APAP) VICOPROFEN (hydrocodone/ibuprofen) XODOL (hydrocone/acetaminophen) ZYDONE (hydrocodone/acetaminophen)	Three of the preferred agents must be tried for at least 72 hours before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Fentanyl lozenges will only be approved as an adjunct to a long-acting agent. Fentanyl lozenges will not be approved for monotherapy. Limits: Quantities exceeding 240 tablets per 30 days (8 tablets/day) for agents containing 500 mg of acetaminophen will require a prior authorization.

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 4/1/08
Version 2008.2

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANALGESICS, NARCOTIC - LONG ACTING (Non-parenteral)	fentanyl KADIAN (morphine) methadone morphine ER	AVINZA (morphine) DURAGESIC (fentanyl) MS CONTIN (morphine) OPANA ER (oxymorphone) ORAMORPH SR (morphine) oxycodone ER OXYCONTIN (oxycodone) ULTRAM ER (tramadol)	Three preferred narcotic analgesics, including at least one long-acting agent, must be tried for at least 72 hours before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Exception: Oxycodone ER will be authorized if a diagnosis of cancer is submitted without a trial of the preferred agents.
ANDROGENIC AGENTS	ANDRODERM (testosterone) ANDROGEL (testosterone)	TESTIM (testosterone)	The non-preferred agents will be approved only if one of the exceptions on the PA form is present.
ANGIOTENSIN MODULATORS	ACE INHIBITORS		Each of the preferred agents in the corresponding group with the exception of Direct Renin Inhibitors must be tried for at least two weeks each before a non-preferred agent in that group will be authorized unless one of the exceptions on the PA form is present.
	ALTACE (ramipril) benazepril captopril enalapril fosinopril lisinopril quinapril	ACCUPRIL (quinapril) ACEON (perindopril) CAPOTEN (captopril) LOTENSIN (benazepril) MAVIK (trandolapril) moexipril MONOPRIL (fosinopril) PRINIVIL (lisinopril) ramipril trandolapril UNIVASC (moexipril) VASOTEC (enalapril) ZESTRIL (lisinopril)	
	ACE INHIBITOR COMBINATION DRUGS		
	benazepril/amlodipine benazepril/HCTZ captopril/HCTZ enalapril/HCTZ fosinopril/HCTZ lisinopril/HCTZ quinapril/HCTZ	ACCURETIC (quinapril/HCTZ) CAPOZIDE (captopril/HCTZ) LEXXEL (enalapril/felodipine) LOTENSIN HCT (benazepril/HCTZ) LOTREL (benazepril/amlodipine) moexipril/HCTZ MONOPRIL HCT (fosinopril/HCTZ) PRINZIDE (lisinopril/HCTZ) TARKA (trandolapril/verapamil) UNIRETIC (moexipril/HCTZ) VASERETIC (enalapril/HCTZ) ZESTORETIC (lisinopril/HCTZ)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Requires Clinical PA

NR – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 4/1/08
Version 2008.2

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs)		
	AVAPRO (irbesartan) BENICAR (olmesartan) COZAAR (losartan) DIOVAN (valsartan) MICARDIS (telmisartan)	ATACAND (candesartan) TEVETEN (eprosartan)	
	ARB COMBINATIONS		
	AVALIDE (irbesartan/HCTZ) BENICAR-HCT (olmesartan/HCTZ) DIOVAN-HCT (valsartan/HCTZ) EXFORGE (valsartan/amlodipine) HYZAAR (losartan/HCTZ) MICARDIS-HCT (telmisartan/HCTZ)	ATACAND-HCT (candesartan/HCTZ) AZOR (olmesartan/amlodipine) TEVETEN-HCT (eprosartan/HCTZ)	
	DIRECT RENIN INHIBITORS		
	TEKTURNA (aliskerin)	A thirty-day trial of one of the preferred ACE, ARB, or combination agents, at the maximum tolerable dose, is required before Tekturna will be approved.	
ANTICOAGULANTS, INJECTABLE ^{CL}	ARIXTRA (fondaparinux) FRAGMIN (dalteparin) LOVENOX (enoxaparin)	INNOHEP (tinzaparin)	A trial of each of the preferred agents will be required before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 4/1/08
Version 2008.2

ANTICONVULSANTS	ADJUVANTS		<p>Treatment naive patients must have a trial of a preferred agent before a non-preferred agent in its corresponding class will be authorized. Additions to that therapy will require a trial of preferred agent in its respective class unless one of the exceptions on the PA form is present.</p> <p>The following step therapy edits will be applied to Lyrica. Lyrica will automatically be approved if there is a history of gabapentin utilization for 60 days, with a gap in therapy of no greater than 30 days. Overrides for Lyrica will not be given unless the dosage of gabapentin has been maximized to 1800 mg/ 24 hour for a diagnosis of chronic or neuropathic pain.</p>
	carbamazepine CARBATROL (carbamazepine) DEPAKOTE (divalproex) DEPAKOTE ER (divalproex) DEPAKOTE SPRINKLE (divalproex) FELBATOL (felbamate) gabapentin GABITRIL (tiagabine) KEPPRA (levetiracetam) LAMICTAL (lamotrigine) LYRICA (pregabalin) ^{CL} TOPAMAX (topiramate) TRILEPTAL (oxcarbazepine) valproic acid zonisamide	DEPAKENE (valproic acid) EQUETRO (carbamazepine) lamotrigine NEURONTIN (gabapentin) oxcarbazepine TEGRETOL (carbamazepine) TEGRETOL XR (carbamazepine) ZONEGRAN (zonisamide)	
	BARBITURATES		
	mephobarbital phenobarbital primidone	MEBARAL (mephobarbital) MYSOLINE (primidone)	
	BENZODIAZEPINES		
	clonazepam DIASTAT (diazepam rectal) diazepam	KLONOPIN (clonazepam)	
	HYDANTOINS		
	DILANTIN INFATABS (phenytoin) PEGANONE (ethotoin) phenytoin	CEREBYX (fosphenytoin) DILANTIN (phenytoin) EPITOL (phenytoin) PHENYTEK (phenytoin)	
	SUCCINIMIDES		
	CELONTIN (methsuximide) ethosuximide	ZARONTIN (ethosuximide)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 4/1/08
Version 2008.2

ANTIDEPRESSANTS, OTHER (second generation, non-SSRI)	bupropion SR CYMBALTA (duloxetine) EFFEXOR XR (venlafaxine) mirtazapine trazodone	bupropion IR bupropion XL DESYREL (trazodone) EFFEXOR (venlafaxine) EMSAM (selegiline) nefazodone REMERON (mirtazapine) venlafaxine WELLBUTRIN (bupropion) WELLBUTRIN SR (bupropion) WELLBUTRIN XL (bupropion)	A non-preferred agent will only be authorized if there has been a six-week trial of an SSRI and a preferred agent in this class unless one of the exceptions on the PA form is present.
ANTIDEPRESSANTS, SSRIs	citalopram fluoxetine fluvoxamine paroxetine sertraline	CELEXA (citalopram) LEXAPRO (escitalopram) PAXIL (paroxetine) PAXIL CR (paroxetine) PEXEVA (paroxetine) PROZAC (fluoxetine) RAPIFLUX (fluoxetine) SARAFEM (fluoxetine) ZOLOFT (sertraline)	A trial of two of the preferred agents will be required, for at least 30 days, before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. Upon hospital discharge, patients admitted with a primary mental health diagnosis and have been stabilized on a non-preferred SSRI will receive authorization to continue that drug.
ANTIEMETICS, ORAL	5HT3 RECEPTOR BLOCKERS		A trial of the preferred agent is required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. PA is required when limits are exceeded.
	ondansetron ZOFTRAN (ondansetron) ZOFTRAN ODT (ondansetron)	ANZEMET (dolasetron) KYTRIL (granisetron) ondansetron ODT	
	CANNABINOIDS		Cesamet will be authorized only for the treatment of nausea and vomiting associated with cancer chemotherapy for patients who have failed to respond adequately to conventional treatments such as promethazine or ondansetron and are over 18 years of age. Marinol will be authorized only for the treatment of anorexia associated with weight loss in patients with AIDS or cancer and unresponsive to megestrol, the prophylaxis of chemotherapy induced nausea and vomiting unresponsive to ondansetron or promethazine and for patients between the ages of 18 and 65 years of age.
		CESAMET (nabilone) MARINOL (dronabinol)	
	SUBSTANCE P ANTAGONISTS		PA is required when limits are exceeded.
EMEND (aprepitant)			

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 4/1/08
Version 2008.2

ANTIFUNGALS, ORAL	clotrimazole fluconazole* ketoconazole ^{CL} nystatin terbinafine ^{CL}	ANCOBON (flucytosine) DIFLUCAN (fluconazole) GRIFULVIN V (griseofulvin) griseofulvin GRIS-PEG (griseofulvin) itraconazole LAMISIL (terbinafine) MYCELEX (clotrimazole) MYCOSTATIN Tablets (nystatin) NIZORAL (ketoconazole) NOXAFIL (posaconazole) SPORANOX (itraconazole) VFEND (voriconazole)	Non-preferred agents will be approved only if one of the exceptions on the PA form is present. *PA is required when limits are exceeded. PA is not required for Grifulvin-V Suspension for children up to 6 years of age for the treatment of tinea capitis.
ANTIFUNGALS, TOPICAL	ANTIFUNGALS		Two of the preferred agents must be tried for at least two weeks each before one of the non-preferred agents will be authorized unless one of the exceptions on the PA form is present.
econazole ketoconazole MENTAX (butenafine) NAFTIN (naftifine) nystatin	ciclopirox ERTACZO (sertaconazole) EXELDERM (sulconazole) LOPROX (ciclopirox) MYCOSTATIN (nystatin) NIZORAL (ketoconazole) OXISTAT (oxiconazole) PENLAC (ciclopirox) SPECTAZOLE (econazole) VUSION (miconazole/petrolatum/zinc oxide) XOLEGEL (ketoconazole)	ANTIFUNGAL/STEROIDCOMBINATIONS	
clotrimazole/betamethasone nystatin/triamcinolone	LOTRISONE (clotrimazole/betamethasone) MYCOLOG (nystatin/triamcinolone)		
ANTI-HISTAMINES, MINIMALLY SEDATING	ANTI-HISTAMINES		A preferred agent, in the age appropriate dosage form, must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
ALAVERT (loratadine) cetirizine (OTC) loratadine TAVIST-ND (loratadine)	ALLEGRA (fexofenadine) CLARINEX Tablets (desloratadine) CLARINEX REDITABS (desloratadine) CLARINEX Syrup (desloratadine) CLARITIN (loratadine) fexofenadine XYZAL (levocetirizine) ZYRTEC (Rx and OTC) (cetirizine) ZYRTEC SYRUP (Rx and OTC) (cetirizine)		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 4/1/08
Version 2008.2

	ANTIHISTAMINE/DECONGESTANT COMBINATIONS		
	ALAVERT-D (loratadine/pseudoephedrine) cetirizine /pseudoephedrine (OTC) loratadine/pseudoephedrine SEMPREX-D (acrivastine/ pseudoephedrine)	ALLEGRA-D (fexofenadine/pseudoephedrine) CLARINEX-D (desloratadine/pseudoephedrine) CLARITIN-D (loratadine/pseudoephedrine) ZYRTEC-D (Rx and OTC) (cetirizine/pseudoephedrine)	
ANTIMIGRAINE AGENTS, TRIPTANS	AMERGE (naratriptan) IMITREX (sumatriptan) MAXALT (rizatriptan) RELPAK (eletriptan)	AXERT (almotriptan) FROVA (frovatriptan) ZOMIG (zolmitriptan)	All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. Quantity limits apply for this drug class.
ANTIPARKINSON'S AGENTS (Oral)	ANTICHOLINERGICS		Patients starting therapy on drugs in this class must show a documented allergy to all of the preferred agents, in the corresponding class, before a non-preferred agent will be authorized.
	benztropine KEMADRIN (procyclidine) trihexyphenidyl	COGENTIN (benztropine)	
	COMT INHIBITORS		
		COMTAN (entacapone) TASMAR (tolcapone)	
	DOPAMINE AGONISTS		
	REQUIP (ropinirole)	MIRAPEX (pramipexole)	
	OTHER ANTIPARKINSON'S AGENTS		
carbidopa/levodopa selegiline STALEVO (levodopa/carbidopa/entacapone)	AZILECT (rasagiline) ELDEPRYL (selegiline) PARCOPA (levodopa/carbidopa) SINEMET (levodopa/carbidopa) ZELAPAR (selegiline)		
ANTIPSYCHOTICS, ATYPICAL (Oral)	ORAL		Treatment naïve patients for this class of drugs will be required to try a preferred agent for two weeks unless one of the exceptions on the PA form is present. Upon discharge, hospitalized patients stabilized on non-preferred agents will receive authorization to continue these drugs for labeled indications and at recommended dosages.
	clozapine GEODON (ziprasidone) INVEGA (paliperidone) RISPERDAL (risperidone) SEROQUEL (quetiapine) SEROQUEL XR (quetiapine)	ABILIFY (aripiprazole) CLOZARIL (clozapine) FAZACLO (clozapine) ZYPREXA (olanzapine)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Requires Clinical PA

NR – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 4/1/08
Version 2008.2

	ATYPICAL ANTIPSYCHOTIC/SSRI COMBINATIONS		
		SYMBYAX (olanzapine/fluoxetine)	
ANTIVIRALS (Oral)	ANTI HERPES		All of the appropriate preferred agents must be tried before the non-preferred agents will be authorized unless one of the exceptions on the PA form is present. All of the appropriate preferred agents must be tried before the non-preferred agents will be authorized unless one of the exceptions on the PA form is present.
	acyclovir VALTREX (valacyclovir)	FAMVIR (famciclovir) ZOVIRAX (acyclovir)	
	ANTI INFLUENZA		
	amantadine	FLUMADINE (rimantadine) RELENZA (zanamivir) rimantadine SYMMETREL (amantadine) TAMIFLU (oseltamivir)	
ATOPIC DERMATITIS	ELIDEL (pimecrolimus) PROTOPIC (tacrolimus)		
BETA BLOCKERS (Oral)	BETA BLOCKERS		If one of the exceptions on the PA form is present or if the physician feels that the patient cannot be stabilized with any of the preferred agents, one of the non-preferred agents will be approved.
	acebutolol atenolol betaxolol bisoprolol metoprolol metoprolol ER nadolol pindolol propranolol propranolol ER sotalol timolol	BETAPACE (sotalol) BLOCADREN (timolol) BYSTOLIC (nebivolol) CARTROL (carteolol) CORGARD (nadolol) INDERAL LA (propranolol) INNOPRAN XL (propranolol) KERLONE (betaxolol) LEVATOL (penbutolol) LOPRESSOR (metoprolol) SECTRAL (acebutolol) TENORMIN (atenolol) TOPROL XL (metoprolol) ZEBETA (bisoprolol)	
	BETA- AND ALPHA-BLOCKERS		
	carvedilol labetalol	COREG (carvedilol) COREG CR (carvedilol) TRANDATE (labetalol)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Requires Clinical PA

NR – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 4/1/08
Version 2008.2

BLADDER RELAXANT PREPARATIONS	ENABLEX (darifenacin) oxybutynin oxybutynin ER OXYTROL (oxybutynin) SANCTURA (trospium) SANCTURA XR (trospium) VESICARE (solifenacin)	DETROL (tolterodine) DETROL LA (tolterodine) DITROPAN (oxybutynin) DITROPAN XL (oxybutynin)	All of the preferred agents in the class must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.	
BONE RESORPTION SUPPRESSION AND RELATED AGENTS	BISPHOSPHONATES		One of the preferred agents must be tried for at least one month before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Evista will be approved for postmenopausal women with osteoporosis or at high risk for invasive breast cancer.	
	FOSAMAX (alendronate) FOSAMAX PLUS D (alendronate/vitamin D)	ACTONEL (risedronate) ACTONEL WITH CALCIUM (risedronate/calcium) BONIVA (ibandronate) DIDRONEL (etidronate)		
	OTHER BONE RESORPTION SUPPRESSION AND RELATED AGENTS			
	MIACALCIN (calcitonin)	EVISTA (raloxifene) FORTEO (teriparatide) FORTICAL (calcitonin)		
BPH AGENTS	5-ALPHA-REDUCTASE (5AR) INHIBITORS		One of the preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.	
	AVODART (dutasteride)	finasteride PROSCAR (finasteride)		
	ALPHA BLOCKERS			
doxazosin FLOMAX (tamsulosin) terazosin UROXATRAL (alfuzosin)	CARDURA (doxazosin) CARDURA XL (doxazosin) HYTRIN (terazosin)			
BRONCHODILATORS, ANTICHOLINERGIC	ANTICHOLINERGIC		The preferred agents in the class must be tried before the non-preferred agent will be authorized unless one of the exceptions on the PA form is present. For severely compromised patients, albuterol/ipratropium will be approved if the combined volume of albuterol and ipratropium nebulas is inhibitory.	
	ATROVENT HFA (ipratropium) ipratropium SPIRIVA (tiotropium)	ATROVENT Inhalation Solution (ipratropium)		
	ANTICHOLINERGIC-BETA AGONIST COMBINATIONS			
	COMBIVENT (albuterol/ipratropium)	albuterol/ipratropium DUONEB (albuterol/ipratropium)		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 4/1/08
Version 2008.2

BRONCHODILATORS, BETA AGONIST	INHALATION SOLUTION		<p>All of the preferred agents in a group must be tried before a non-preferred agent in that group will be authorized unless one of the exceptions on the PA form is present.</p> <p>Xopenex Inhalation Solution will be approved for 12 months for a diagnosis of asthma or COPD for patients on concurrent asthma controller therapy (either oral or inhaled) with documentation of failure on a trial of albuterol or documented intolerance of albuterol, or for concurrent diagnosis of heart disease.</p> <p>**No PA is required for ACCUNEb for children up to 5 years of age.</p>
	albuterol	ACCUNEb (albuterol)** BROVANA (arformoterol) ^{NR} metaproterenol PERFOROMIST (formoterol) ^{NR} PROVENTIL (albuterol) XOPENEX (levalbuterol)	
	INHALERS, LONG-ACTING		
	FORADIL (formoterol)	SEREVENT (salmeterol)	
	INHALERS, SHORT-ACTING		
	albuterol CFC MAXAIR (pirbuterol) PROAIR HFA (albuterol) PROVENTIL HFA (albuterol) VENTOLIN HFA (albuterol) XOPENEX HFA (levalbuterol)	ALUPENT (metaproterenol) PROVENTIL (albuterol)	
	ORAL		
	albuterol terbutaline	BRETHINE (terbutaline) metaproterenol VOSPIRE ER (albuterol)	
CALCIUM CHANNEL BLOCKERS (Oral)	LONG-ACTING		<p>The preferred agents must be tried before a non-preferred agent will be approved.</p>
	amlodipine CARDIZEM LA (diltiazem) diltiazem DYNACIRC CR (isradipine) felodipine ER nifedipine SULAR (nisoldipine) verapamil VERELAN PM (verapamil)	ADALAT CC (nifedipine) CALAN SR (verapamil) CARDENE SR (nicardipine) CARDIZEM CD (diltiazem) CARDIZEM SR (diltiazem) COVERA-HS (verapamil) DILACOR XR (diltiazem) ISOPTIN SR (verapamil) NORVASC (amlodipine) PLENDIL (felodipine) PROCARDIA XL (nifedipine) TIAZAC (diltiazem) VERELAN (verapamil)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 4/1/08
Version 2008.2

	SHORT-ACTING	
	diltiazem verapamil	ADALAT (nifedipine) CALAN (verapamil) CARDENE (nicardipine) CARDIZEM (diltiazem) DYNACIRC (isradipine) isradipine nicardipine nimodipine nifedipine NIMOTOP (nimodipine) PROCARDIA (nifedipine)
CEPHALOSPORINS AND RELATED ANTIBIOTICS (Oral)	BETA LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS	The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	amoxicillin/clavulanate	
	CEPHALOSPORINS	
	cefaclor cefadroxil cefepodoxime cefprozil cefuroxime cephalexin OMNICEF (cefdinir) SPECTRACEF (cefditoren)	CECLOR (cefaclor) CEDAX (ceftibuten) cefdinir CEFTIN (cefuroxime) CEFZIL (cefprozil) DURICEF (cefadroxil) KEFLEX (cephalexin) PANIXINE (cephalexin) RANICLOR (cefaclor) SUPRAX (cefixime) VANTIN (cefpodoxime)
CYTOKINE & CAM ANTAGONISTS ^{CL}	ENBREL (etanercept) HUMIRA (adalimumab) KINERET (anakinra) RAPTIVA (efalizumab)	
ERYTHROPOIESIS STIMULATING PROTEINS ^{CL}	ARANESP (darbepoetin) PROCRIT (rHuEPO)	EPOGEN (rHuEPO)
FLUOROQUINOLONES, ORAL	AVELOX (moxifloxacin) CIPRO (ciprofloxacin) Suspension ciprofloxacin ciprofloxacin ER LEVAQUIN (levofloxacin)	CIPRO (ciprofloxacin) Tablets CIPRO XR (ciprofloxacin) FACTIVE (gemifloxacin) FLOXIN (ofloxacin) NOROXIN (norfloxacin) ofloxacin PROQUIN XR (ciprofloxacin)
		One of the preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 4/1/08
Version 2008.2

GENITAL WARTS AGENTS	ALDARA (imiquimod)	CONDYLOX (podofilox) podofilox VEREGEN (sinecatechins)	
GLUCOCORTICIDS, INHALED	GLUCOCORTICIDS		All of the preferred agents of a dosage form must be tried before a non-preferred agent of that dosage form will be authorized unless one of the exceptions on the PA form is present. Pulmicort Respules do not require a prior authorization for children through 8 years of age or for individuals unable to use an MDI. When children who have been stabilized on Pulmicort Respules reach age 9, prescriptions for the Pulmicort inhaler will be authorized for them.
	AEROBID (flunisolide) AEROBID-M (flunisolide) ASMANEX (mometasone) AZMACORT (triamcinolone) FLOVENT HFA (fluticasone) QVAR (beclomethasone)	PULMICORT (budesonide)	
	GLUCOCORTICOID/BRONCHODILATOR COMBINATIONS		
	ADVAIR (fluticasone/salmeterol) ADVAIR HFA (fluticasone/salmeterol)	SYMBICORT(budesonide/formoterol)	
GROWTH HORMONE^{CL}	GENOTROPIN (somatropin) NORDITROPIN (somatropin) NUTROPIN (somatropin) NUTROPIN AQ (somatropin) SAIZEN (somatropin) TEV-TROPIN (somatropin)	HUMATROPE (somatropin) INCRELEX (mecasermin) OMNITROPE (somatropin) SEROSTIM (somatropin) ZORBTIVE (somatropin)	The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Patients already on a non-preferred agent will receive authorization to continue therapy on that agent for the duration of the existing PA.
HEPATITIS B TREATMENTS	EPIVIR HBV (lamivudine) HEPSERA (adefovir) TYZEKA (telbivudine)	BARACLUDE (entecavir)	One of the preferred agents must be tried before the non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
HEPATITIS C TREATMENTS^{CL}	PEGASYS (pegylated interferon) ribavirin	COPEGUS (ribavirin) INFERGEN (consensus interferon) PEG-INTRON (pegylated interferon) REBETOL (ribavirin)	Patients starting therapy in this class must try preferred agent of a dosage form before a non-preferred agent of that dosage form will be authorized.
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS	BYETTA (exenatide) JANUMET (sitagliptin/metformin) JANUVIA (sitagliptin) SYMLIN (amylin)		Byetta and Symlin are both subject to the following step therapy edits: Byetta-Current history of therapy with a sulfonyleurea, thiazolidinedione (TZD), and/or metformin. No gaps of therapy greater than 30 days in the past 180 days. Symlin- History of insulin utilization in the past 90 days. No gaps in therapy of greater than 30 days.

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 4/1/08
Version 2008.2

HYPOGLYCEMICS, INSULINS	HUMALOG (insulin lispro) HUMALOG MIX (insulin lispro/lispro protamine) HUMULIN (insulin) LANTUS (insulin glargine) LEVEMIR (insulin detemir) NOVOLIN (insulin) NOVOLOG (insulin aspart) NOVOLOG MIX (insulin aspart/aspart protamine)	APIDRA (insulin glulisine) HUMALOG KWIKPEN (insulin lispro) ^{NR}	To receive Apidra, patients must meet the following criteria: 1. be 18 years or older; 2. be currently on a regimen including a longer-acting or basal insulin. 3. have had a trial of a similar preferred agent, Novolog or Humulin, with documentation that the desired results were not achieved.	
HYPOGLYCEMICS, MEGLITINIDES	STARLIX (nateglinide)	PRANDIN (repaglinide)	The preferred agent must be tried before a non-preferred agent will be authorized, unless one of the exceptions on the PA form is present.	
HYPOGLYCEMICS, TZDS	THIAZOLIDINEDIONES			
	ACTOS (pioglitazone) AVANDIA (rosiglitazone)			
	TZD COMBINATIONS			
	ACTOPLUS MET (pioglitazone/metformin) AVANDAMET (rosiglitazone/metformin) AVANDARYL (rosiglitazone/glimepiride) DUETACT (pioglitazone/glimepiride)			
IMPETIGO AGENTS, TOPICAL	ALTABAX (retapamulin) bacitracin gentamycin sulfate mupirocin	BACTROBAN (mupirocin) CORTISPORIN (bacitracin/neomycin/polymyxin/HC)		
INTRANASAL RHINITIS AGENTS	ANTICHOLINERGICS		All of the preferred agents, in corresponding categories, must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.	
		ATROVENT(ipratropium) ipratropium		
	ANTI HISTAMINES			
	ASTELIN (azelastine)			
	CORTICOSTEROIDS			
fluticasone propionate NASACORT AQ (triamcinolone) NASONEX (mometasone) VERAMYST (fluticasone furoate)	BECONASE AQ (beclomethasone) flunisolide FLONASE (fluticasone propionate) NASALIDE (flunisolide) NASAREL (flunisolide) RHINOCORT AQUA (budesonide)			

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 4/1/08
Version 2008.2

LEUKOTRIENE MODIFIERS	ACCOLATE (zafirlukast) SINGULAIR (montelukast)	ZYFLO (zileuton)	The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
LIPOTROPICS, OTHER (non-statins)	BILE ACID SEQUESTRANTS		The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Zetia, as monotherapy, will only be approved for patients who cannot take statins or other preferred agents. Zetia and Welchol will be approved for add-on therapy only after an insufficient response to the maximum tolerable dose of a statin after 12 weeks of therapy. If patients require the addition of Zetia to Zocor to achieve goal, use of the combination product, Vytorin, will be required. If patients are on other statins and require the addition of Zetia, patients will not be required to switch the statin that they have been using.
	cholestyramine colestipol	COLESTID (colestipol) QUESTRAN (cholestyramine) WELCHOL (colesevalam)	
	CHOLESTEROL ABSORPTION INHIBITORS		
		ZETIA (ezetimibe)	
	FATTY ACIDS		
		OMACOR (omega-3-acid ethyl esters)	
	FIBRIC ACID DERIVATIVES		
	fenofibrate gemfibrozil TRICOR (fenofibrate)	ANTARA (fenofibrate) LOFIBRA (fenofibrate) LOPID (gemfibrozil) TRIGLIDE (fenofibrate)	
	NIACIN		
	niacin NIASPAN (niacin)	NIACELS (niacin) NIADELAY (niacin) SLO-NIACIN (niacin)	
LIPOTROPICS, STATINS	STATINS		One of the preferred statins must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	CRESTOR (rosuvastatin) LESCOL (fluvastatin) LESCOL XL (fluvastatin) LIPITOR (atorvastatin) lovastatin pravastatin simvastatin	ALTOPREV (lovastatin) MEVACOR (lovastatin) PRAVACHOL (pravastatin) ZOCOR (simvastatin)	
	STATIN COMBINATIONS		
	ADVICOR (lovastatin/niacin) CADUET (atorvastatin/amlodipine)	VYTORIN (ezetimibe/simvastatin)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 4/1/08
Version 2008.2

MACROLIDES/KETOLIDES (Oral)	KETOLIDES		Requests for telithromycin will be authorized if there is documentation of the use of any antibiotic within the past 28 days. The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
		KETEK (telithromycin)	
	MACROLIDES		
	azithromycin clarithromycin erythromycin	BIAXIN (clarithromycin) BIAXIN XL (clarithromycin) clarithromycin ER E. E.S. (erythromycin ethylsuccinate) E-MYCIN (erythromycin) ERYC (erythromycin) ERYPED (erythromycin ethylsuccinate) ERY-TAB (erythromycin) ERYTHROCIN (erythromycin stearate) erythromycin estolate PCE (erythromycin) ZITHROMAX (azithromycin) ZMAX (azithromycin)	
MULTIPLE SCLEROSIS AGENTS^{CL}	AVONEX (interferon beta-1a) BETASERON (interferon beta-1b) COPAXONE (glatiramer) REBIF (interferon beta-1a)	TYSABRI (natalizumab)	TBD

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 4/1/08
Version 2008.2

NSAIDS	NONSELECTIVE		The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	diclofenac etodolac fenoprofen flurbiprofen ibuprofen (Rx and OTC) indomethacin ketorolac naproxen (Rx only) oxaprozin piroxicam sulindac	ADVIL (ibuprofen) ANAPROX (naproxen) ANSAID (flurbiprofen) CATAFLAM (diclofenac) CLINORIL (sulindac) DAYPRO (oxaprozin) FELDENE (piroxicam) INDOCIN (indomethacin) ketoprofen LODINE (etodolac) meclofenamate mefenamic acid MOTRIN (ibuprofen) nabumetone NALFON (fenoprofen) NAPRELAN (naproxen) NAPROSYN (naproxen) NUPRIN (ibuprofen) ORUDIS (ketoprofen) PONSTEL (meclofenamate) tolmetin VOLTAREN (diclofenac)	
	NSAID/GI PROTECTANT COMBINATIONS		
		ARTHROTEC (diclofenac/misoprostol) PREVACID/NAPRAPAC (naproxen/lansoprazole)	
	COX-II SELECTIVE^{CL}		
	CELEBREX (celecoxib) meloxicam MOBIC (meloxicam)	COX-II selective NSAIDs will be approved for patients with a GI Risk Score of ≥ 13 .	
OPHTHALMIC FLUOROQUINOLONES	ciprofloxacin ofloxacin VIGAMOX (moxifloxacin)	CILOXAN (ciprofloxacin) OCUFLOX (ofloxacin) QUIXIN (levofloxacin) ZYMAR (gatifloxacin)	All of the preferred agents must be tried before non-preferred agents will be authorized unless one of the exceptions on the PA form is present.

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 4/1/08
Version 2008.2

OPHTHALMIC NSAIDS	ACULAR LS (ketorolac) ACULAR PF (ketorolac) flurbiprofen NEVANAC (nepafenac) XIBROM (bromfenac)	diclofenac	All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS	ACULAR (ketorolac) ALAWAY (ketotifen) ALREX (loteprednol) cromolyn ELESTAT (epinastine) OPTIVAR (azelastine) PATADAY (olopatadine) PATANOL (olopatadine) ZADITOR OTC (ketotifen)	ALAMAST (pemirolast) ALOCRIL (nedocromil) ALOMIDE (lodoxamide) CROLOM (cromolyn) EMADINE (emedastine) ketotifen OPTICROM (cromolyn)	Two of the preferred agents must be tried before non-preferred agents will be authorized, unless one of the exceptions on the PA form is present.
OPHTHALMICS, GLAUCOMA AGENTS	COMBINATION AGENTS		Authorization for a non-preferred agent will only be given if there is an allergy to the preferred agents.
	COSOPT (dorzolamide/timolol)		
	BETA BLOCKERS		
	Betaxolol BETIMOL (timolol) BETOPTIC S (betaxolol) carteolol ISTALOL (timolol) levobunolol metipranolol timolol	BETAGAN (levobunolol) OPTIPRANOLOL (metipranolol) TIMOPTIC (timolol)	
	CARBONIC ANHYDRASE INHIBITORS		
	AZOPT (brinzolamide) TRUSOPT (dorzolamide)		
	PARASYMPATHOMIMETICS		
	CARBOPTIC (carbachol) ISOPTO CARBACHOL (carbachol) PHOSPHOLINE IODIDE (echothiophate iodide) pilocarpine	ISOPTO CARPINE (pilocarpine) PILOPINE HS (pilocarpine)	
	PROSTAGLANDIN ANALOGS		
	LUMIGAN (bimatoprost) TRAVATAN (travoprost) TRAVATAN-Z (travaprost)	XALATAN (latanoprost)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 4/1/08
Version 2008.2

SYMPATHOMIMETICS			
	ALPHAGAN P (brimonidine) brimonidine dipivefrin	ALPHAGAN (brimonidine) PROPINE (dipivefrin)	
OTIC FLUOROQUINOLONES	CIPRODEX (ciprofloxacin/dexamethasone) FLOXIN (ofloxacin)	CIPRO HC (ciprofloxacin/hydrocortisone) ofloxacin	All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.
PANCREATIC ENZYMES	PANCRECARB ULTRASE ULTRASE MT VIOKASE	CREON KUZYME LIPRAM PALCAPS PANCREASE PANGESTYME PANOKASE PLARETASE	
PARATHYROID AGENTS	ergocalciferol calcitriol HECTOROL (doxercalciferol) ZEMPLAR (paricalcitol)	DRISDOL (ergocalciferol) ROCALTROL (calcitriol) SENSIPAR (cinacalcet)	
PEDICULICIDES/ SCABICIDES, TOPICAL	EURAX (crotamiton) OVIDE (malathion) permethrins (Rx and OTC) pyrethrins-piperonyl butoxide	lindane	
PHOSPHATE BINDERS	FOSRENOL (lanthanum) PHOSLO (calcium acetate) RENAGEL (sevelamer)	REVELA (sevelamer carbonate) ^{NR}	
PLATELET AGGREGATION INHIBITORS	AGGRENOX (dipyridamole/ASA) PLAVIX (clopidogrel)	dipyridamole PERSANTINE (dipyridamole) TICLID (ticlopidine) ticlopidine	All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 4/1/08
Version 2008.2

PROTON PUMP INHIBITORS	NEXIUM (esomeprazole) PREVACID Capsules (lansoprazole)	ACIPHEX (rabeprazole) omeprazole pantoprazole PREVACID Solu-Tabs (lansoprazole) PREVACID Suspension (lansoprazole) PRILOSEC (omeprazole) PROTONIX (pantoprazole) ZEGERID (omeprazole/sodium bicarbonate)	The preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. Prior authorization is not required for Prevacid Solu-Tabs for patients ≤8 years of age.
SEDATIVE HYPNOTICS	BENZODIAZEPINES		The preferred agent must be tried for 14 days before a nonpreferred agent will be authorized unless one of the exceptions on the PA form is present.
	temazepam	DALMANE (flurazepam) DORAL (quazepam) estazolam flurazepam HALCION (triazolam) PROSOM (estazolam) RESTORIL (temazepam) triazolam	
	OTHERS		
	zolpidem	AMBIEN (zolpidem) AMBIEN CR (zolpidem) AQUA CHLORAL (chloral hydrate) chloral hydrate LUNESTA (eszopiclone) ROZEREM (ramelteon) SOMNOTE (chloral hydrate) SONATA (zaleplon)	
STIMULANTS AND RELATED AGENTS	AMPHETAMINES		Except for Strattera, PA is required for adults >18 years. One of the preferred agents in each group (amphetamines and non-amphetamines) must be tried before a non-preferred agent will be authorized.
	ADDERALL XR (amphetamine salt combination) amphetamine salt combination dextroamphetamine VYVANSE (lisdexamphetamine)	ADDERALL (amphetamine salt combination) DESOXYN (methamphetamine) DEXEDRINE (dextroamphetamine) DEXTROSTAT (dextroamphetamine)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 4/1/08
Version 2008.2

	NON-AMPHETAMINE		
	CONCERTA (methylphenidate) DAYTRANA (methylphenidate) FOCALIN (dexamethylphenidate) FOCALIN XR (dexamethylphenidate) METADATE CD (methylphenidate) methylphenidate methylphenidate ER STRATTERA (atomoxetine)	dexamethylphenidate METADATE ER (methylphenidate) pemoline PROVIGIL (modafanil) RITALIN (methylphenidate) RITALIN LA (methylphenidate) RITALIN-SR (methylphenidate)	Amphetamines will be authorized for the treatment of depression only after documented failure of multiple antidepressants. Provigil will only be approved for patients >16 years of age with a diagnosis of narcolepsy. Strattera will not be approved for concurrent administration with amphetamines or methylphenidates, except for 30 days or less for tapering purposes. Only two doses of each strength, or two concurrent doses of any strength, and a maximum of one dose of a 60 mg capsule, will be approved in a 34-day period.
ULCERATIVE COLITIS AGENTS	ORAL		The preferred agents of a dosage form must be tried before a non-preferred agent of that dosage form will be authorized unless one of the exceptions on the PA form is present.
	ASACOL (mesalamine) COLAZAL (balsalazide) DIPENTUM (olsalazine) PENTASA (mesalamine) sulfasalazine	AZULFIDINE (sulfasalazine) LIALDA (mesalamine)	
	RECTAL		
	CANASA (mesalamine) mesalamine	ROWASA (mesalamine)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee